MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Votrient (pazopanib)

Company: GlaxoSmithKline
Approval Status: Approved April 2012
Treatment for: soft tissue sarcoma
Areas: Musculoskeletal; Cancer & Oncology
Possible similar drugs: Votrient

| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |


General Information

Votrient (pazopanib) is a vascular epidermal growth factor receptor (VEGFR) tyrosine kinase inhibitor which acts at all three isoforms: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF is a chemical signal produced by cells that stimulates the growth of new blood vessels. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. When VEGF is overexpressed, it can contribute to disease. Solid cancers need an adequete blood supply or they will not be able to grow. Hence, cancer that can express VEGF are able to grow and metastasize.

Votrient is specifically indicated for the treatment of advanced soft tissue sarcoma in patients who have received chemotherapy.

Votrient is supplied as a tablet designed for oral administration. The recommended initial dose is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). The dose of Votrient should not exceed 800 mg.


Clinical Results

FDA Approval
The FDA Approval of Votrient was based on the results of a randomized, double-blind, placebo-controlled, multicenter trial named PALETTE. The study enrolled 369 subjects with soft tissue sarcoma (STS) who did not respond to previous chemotherapy treatment or who were ineligible for chemotherapy treatment. Subjects with adipocytic STS or gastrointestinal stromal tumors were excluded from the trial. Subjects were randomized 2:1 to be treated with Viotrent 800 mg per day or placebo. The primary efficacy endpoint was the rate of progression-free survival (PFS) and was assessed by independent radiological review. Secondary efficacy endpoints included overall survival (OS), overall response rate, and duration of response. The median duration of PFS among the Votrient arm was 4.6 months against 1.6 months in the placebo arm. The overall response rate in the treatment group was 4% for a duration of 9 months compared to 0% in the placebo group.


Side Effects

Adverse reactions associated with the use of Votrient may include, but are not limited to, the following:

  • fatigue
  • diarrhea
  • nausea
  • decreased weight
  • hypertension
  • decreased appetite
  • vomiting
  • tumor pain
  • hair color changes
  • musculoskeletal pain
  • headache
  • dysgeusia
  • dyspnea
  • skin hypopigmentation


Mechanism of Action

Votrient (pazopanib) is a vascular epidermal growth factor receptor (VEGFR) tyrosine kinase inhibitor which acts at all three isoforms: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF is a chemical signal produced by cells that stimulates the growth of new blood vessels. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. When VEGF is overexpressed, it can contribute to disease. Solid cancers need an adequete blood supply or they will not be able to grow. Hence, cancer that can express VEGF are able to grow and metastasize.


Additional Information

For additional information regarding Votrient or soft tissue sarcoma, please visit the Votrient web page.




< back to top

Votrient Drug Information

The Votrient drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.